GlassScriptPhysician profile
Kaitlan Griffith
NPI 1629534870
$6,419.14
in general payments reported to CMS, 2019-2025
26 companies · $377 in 2025
The $377 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $603 · 2022: $1,172 · 2023: $2,063 · 2024: $2,204 · 2025: $377.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,644.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,644.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,200.07 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $581.30 | 2022-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $573.16 | 2023-2024 | Austedo Xr, Austedo |
| Axsome Therapeutics, INC. | $555.62 | 2023-2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $461.67 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Janssen Pharmaceuticals, INC | $425.30 | 2022-2025 | Spravato |
| Idorsia Pharmaceuticals US INC | $365.77 | 2022-2024 | Quviviq |
| Alkermes, INC. | $283.94 | 2022-2025 | Aristada, Lybalvi |
| Eisai INC. | $269.22 | 2021 | |
| Lundbeck LLC | $239.53 | 2022-2024 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $194.32 | 2023-2024 | Trintellix |
| Neuronetics, INC. | $183.86 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $174.79 | 2022-2025 | Caplyta |
| Corium, LLC | $155.34 | 2023-2024 | Azstarys |
| Tris Pharma INC | $110.78 | 2022-2025 | Dyanavel Xr |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $110.36 | 2021 | |
| Almatica Pharma LLC | $110.31 | 2024-2025 | Loreev Xr, Teriparatide |
| Biogen, INC. | $95.00 | 2023 | |
| Neos Therapeutics, LP | $75.59 | 2023-2024 | Adzenys Xr-Odt |
| Noven Therapeutics, LLC | $68.15 | 2024 | Xelstrym |
| Ironshore Pharmaceuticals INC. | $48.94 | 2023-2024 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $40.04 | 2023-2025 | Qelbree, Qelbree |
| Vanda Pharmaceuticals INC. | $35.94 | 2025 | Fanapt, Hetlioz |
| Bausch Health US, LLC | $21.15 | 2025 | Aplenzin |
| Collegium Pharmaceutical, INC. | $19.97 | 2025 | Jornay Pm |
| Noven Pharmaceuticals, INC. | $19.02 | 2024 | Xelstrym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kaitlan Griffith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.